NEW YORK–(BUSINESS WIRE)–Viramal(“the Company”), an emerging specialty pharmaceutical company
developing therapeutics that improve the quality of women’s health,
today announced that the Company’s CEO, Oliver Bates, will present at
the 18th Annual BIO CEO & Investor Conference. The presentation will
take place on Monday, February 8, 2016 at 4:00 p.m. ET in the Park North
room at The Waldorf Astoria in New York City. Mr. Bates will be joined
by Viramal’s Chairman, William Bologna.
Mr. Bates will outline Viramal’s robust women’s health clinical
development pipeline and strategy to produce a step change in existing
female healthcare products, as well as develop innovative products that
target unmet therapeutic areas, by leveraging novel platform delivery
technologies that offer greater safety and efficacy. The presentation
will be available in the “News”
section of the Company’s website, www.viramal.com.
To schedule a meeting with Viramal’s management team at the conference,
use the BIO
CEO one-on-one meeting portal for registered participants or contact
Katja Buhrer in the Investor Relations department at firstname.lastname@example.org.
Viramal is an emerging specialty pharmaceutical company focused on the
development of therapeutics that improve the quality of women’s health.
The Company’s well-recognized management team has pioneered
market-leading products in fertility and female sexual health, having
successfully developed and licensed Crinone®, Replens® and RepHresh®.
Viramal produces a step change in these existing products, as well as
develops innovative products that target unmet therapeutic areas, by
leveraging novel platform delivery technologies that offer greater
safety, efficacy and patient acceptability with far fewer side effects.
The Company’s robust women’s health clinical development pipeline
includes treatments for fertility, menopausal hormone therapy,
contraception and sexual health. In addition, Viramal’s only male
product, TestoCream (transdermal delivery of testosterone), has shown
81% success in a partially completed Phase III study. Please visit www.viramal.com
for more information.
About the BIO CEO & Investor Conference
Now in its eighteenth year, the BIO CEO & Investor Conference is the
largest investor conference focused on established and emerging publicly
traded and select private biotech companies. Each year this conference
provides a neutral forum where institutional investors, industry
analysts, and senior biotechnology executives have the opportunity to
shape the future investment landscape of the biotechnology industry. The
conference will be held February 8-9, 2016 at the Waldorf Astoria in New
MBS Value Partners
Buhrer, (212) 661-7004